[{"arm_notes": "", "treatment_id": null, "treatment_name": "All subjects recruited shall have received two doses of the ChAdOx1 (AZD1222) vaccine for at least 3 months. All participants were received one dose of Recombinant COVID-19 Vaccine (CHO cells) (25 mcg; 0.5 mL). ;All subjects recruited shall have received two doses of the heterologous prime-boost with CoronaVac and AZD1222 vaccine for at least three months. All participants were received one dose of Recombinant COVID-19 Vaccine (CHO cells) (25 mcg; 0.5 mL).;Active Comparator Drug;Active Comparator Drug;ZF2001 protein subunit vaccine in homologous AZD1222;ZF2001 protein subunit vaccine in heterologous CoronaVac/AZD1222", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": " two doses of the ChAdOx1", "treatment_id": 1738, "treatment_name": "Zf2001", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": " CoronaVac +ChAdOx1", "treatment_id": 1738, "treatment_name": "Zf2001", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]